NERV Stock Forecast: Minerva Neurosciences, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Minerva Neurosciences, Inc. is $10. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 28 of 100 as at 18 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Minerva Neurosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (70): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
NERV stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on NERV, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 1 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Aug 2026 | Jefferies | Upgrade | Buy | $7.50 → $10 |
| 15 Apr 2026 | Citizens | Initiates | Market Outperform | $14 |
| 12 Mar 2026 | HC Wainwright & Co. | Maintains | Neutral | — |
| 6 Nov 2025 | HC Wainwright & Co. | Maintains | Neutral | — |
| 26 Feb 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 6 Nov 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 7 Aug 2024 | HC Wainwright & Co. | Maintains | Neutral | — |
| 2 May 2024 | HC Wainwright & Co. | Maintains | Neutral | — |
| 27 Feb 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 2 Aug 2023 | HC Wainwright & Co. | Maintains | Neutral | — |
| 16 May 2023 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 2 May 2023 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 9 Mar 2023 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 10 Nov 2022 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 17 Oct 2022 | JMP Securities | Downgrade | Market Perform | — |
| 4 Mar 2022 | HC Wainwright & Co. | Maintains | Buy | $10 → $5.00 |
| 8 June 2020 | HC Wainwright & Co. | Maintains | Buy | $20 → $10 |
| 19 Dec 2019 | H.C. Wainwright | Reiterates | Buy | — |
| 19 Dec 2019 | HC Wainwright & Co. | Reiterates | Buy | $22 → $20 |
| 19 Dec 2019 | JMP Securities | Maintains | Market Outperform | $20 → $18 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for NERV.
This page is one stock. Monday covers all of them.
NERV appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
NERV vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 19 Nov 2026, Minerva Neurosciences, Inc. returned −50.7% against +9.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
NERV analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- −34.7%
- Dividend yield
- —
Higher than 12% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Minerva Neurosciences, Inc. has a market value of $107.6M and an enterprise value of $102.4M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$394.3M.
Diluted earnings per share, trailing twelve months: −$28.87.
Free cash flow in the twelve months to 30 June 2026: −$26.2M.
Minerva Neurosciences, Inc. employs 7 people.
Data provided by Twelve Data
NERV and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at NERV’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Minerva Neurosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about NERV
What is the NERV stock price forecast for 2026-2027?
The median 12-month analyst price target for Minerva Neurosciences, Inc. is $10, with estimates ranging from $7 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is NERV stock a buy right now?
Of the 3 analysts covering Minerva Neurosciences, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Minerva Neurosciences, Inc. 28 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank NERV?
As at 18 Nov 2026, Minerva Neurosciences, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (70 of 100).
Will NERV stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts is $10, and Ticker Nerd's factor model ranks Minerva Neurosciences, Inc. 28 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the NERV stock forecast for 2030?
No analyst covering Minerva Neurosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NERV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $14 over the next 12 months.
How has NERV stock performed over the past year?
Minerva Neurosciences, Inc. returned -50.7% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Minerva Neurosciences, Inc. do?
Minerva Neurosciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. Its current pipeline centers on roluperidone, a product candidate being studied for the treatment of negative symptoms in schizophrenia, and other CNS-related programs such as seltorexant.
About Minerva Neurosciences, Inc.
Minerva Neurosciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. Its current pipeline centers on roluperidone, a product candidate being studied for the treatment of negative symptoms in schizophrenia, and other CNS-related programs such as seltorexant. The company’s work is concentrated on advancing proprietary medicines through clinical development and regulatory pathways, with an emphasis on conditions where treatment options remain limited. Minerva Neurosciences serves a specialized role in the biopharmaceutical market by targeting neuropsychiatric and neurological diseases that affect patients, clinicians, and healthcare systems worldwide. Headquartered in Burlington, Massachusetts, Minerva Neurosciences operates as a research-driven company whose primary business is the development and commercialization of product candidates for complex brain and nervous system disorders.
CEO Dr. Remy Luthringer Ph.D. · 7 employees · United States · https://www.minervaneurosciences.com